The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells

Effect of Topotecan as Second-Line Chemotherapy for Small Cell Lung Cancer Patients with Interstitial Lung Disease

(2014) H.- Suzuki et al.   JOURNAL OF CHEMOTHERAPY

Hypoxia and Hypoxia-Inducible Factor-1  Modulate Lipopolysaccharide-Induced Dendritic Cell Activation and Function

(2014) J. Jantsch et al.   JOURNAL OF IMMUNOLOGY

DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets

(2012) M. Alagoz et al.   CURRENT MEDICINAL CHEMISTRY

Management of Small Cell Lung Cancer

(2012) Raffaele Califano et al.   DRUGS

Regulatory dendritic cells in the tumor immunoenvironment

(2011) Galina V. Shurin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1  in Advanced Solid Tumors

(2011) S. Kummar et al.   CLINICAL CANCER RESEARCH

Antigen-Presenting Cell (APC) Subsets in Ovarian Cancer

(2011) Cailin Moira Wilke et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma

(2010) D. Aoki et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

(2010) Jalid Sehouli et al.   JOURNAL OF CLINICAL ONCOLOGY

Programming dendritic cells to induce TH2 and tolerogenic responses

(2010) Bali Pulendran et al.   NATURE IMMUNOLOGY

Review role of topotecan in gynaecological cancers: Current indications and perspectives

(2009) Domenica Lorusso et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Current role and future aspects of topotecan in relapsed ovarian cancer

(2009) Jalid Sehouli et al.   CURRENT MEDICAL RESEARCH AND OPINION

A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2Administered Weekly as a 30-Minute Intravenous Infusion in Patients With Cancer

(2009) Kelly K. Curtis et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Hypoxia stimulus: An adaptive immune response during dendritic cell maturation

(2008) I. Rama et al.   KIDNEY INTERNATIONAL

Supernatant from Bifidobacterium Differentially Modulates Transduction Signaling Pathways for Biological Functions of Human Dendritic Cells

(2008) Cyrille Hoarau et al.   PLoS One